Related Experiment Video
Updated: Jun 23, 2026
A Rhodopsin Transport Assay by High-Content Imaging Analysis
Published on: January 16, 2019
Clinical Research for Inherited Retinal Disease Related Pediatric Blindness: A Preliminary Descriptive Analysis Based
Ahmed M Ashour1,2, Maan H Harbi1, Fahad S Alshehri1,2
1Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Insights
Current clinical trials offer new hope for treating childhood blindness with targeted gene and pharmacological therapies. Further research is needed to expand these promising early-phase studies for better outcomes.
Area of Science:
- Ophthalmology
- Genetics
- Clinical Research
Background:
- Childhood blindness is a major global health issue, often caused by rare genetic and congenital disorders.
- Advances in gene therapy and pharmacology are driving new clinical research for childhood blindness treatments.
- This study provides a preliminary analysis of clinical trials focused on childhood blindness treatments.
Purpose of the Study:
- To conduct a descriptive analysis of clinical trials for childhood blindness.
- To explore current trends in interventional studies for pediatric visual impairment.
- To identify common conditions, interventions, and outcomes in childhood blindness research.
Main Methods:
- A cross-sectional analysis of data from ClinicalTrials.gov was performed.
- Searched for blindness-related studies, filtering for interventional trials targeting childhood blindness (2012-2023).
- Extracted and analyzed key characteristics: conditions, interventions, outcomes, phases, and enrollment.
Main Results:
- Five interventional trials met the inclusion criteria, primarily investigating rare genetic conditions.
- Common interventions included gene therapy (AAV RPE65), antisense oligonucleotides (QR-110), and repurposed drugs (lithium, dantrolene sodium).
- Most trials were early-phase (Phase 1/2) with small sample sizes, focusing on safety and visual function outcomes.
Conclusions:
- Current clinical trials show promise for targeted childhood blindness therapies.
- The predominance of early-phase trials necessitates more extensive, later-phase, and multicenter studies.
- Future research should focus on improving trial accessibility, standardizing outcomes, and ensuring ethical pediatric research.
Background:
Childhood blindness is a significant global health concern, consistently identified in existing research as stemming from rare genetic and congenital disorders. With the technological advances of the 21st century which have positively impacted many areas of human life, healthcare included, recent advances in gene therapy and pharmacological interventions have served to spur clinical research in this area. The primary focus of the current study was to use data from ClinicalTrials.gov to carry out a preliminary exploration and and descriptive analysis of clinical trials focusing on the treatment of childhood blindness.
Methods:
A cross-sectional analysis was conducted using data from ClinicalTrials.gov. The initial search for data in ClinicalTrials.gov yielded a total of 110 studies under blindness-related conditions. Upon further cross-examination of these studies based on the inclusion criteria, only five interventional trials (published between 2012 and 2023) specifically targeting childhood blindness met the inclusion criteria and were therefore included. Key trial characteristics studied conditions, intervention types, outcome measures, study phases, and enrollment sizes were extracted and analyzed descriptively.
Results:
Across the five included trials, a majority of trials investigated rare genetic conditions, including Leber Congenital Amaurosis, Wolfram Syndrome, and Osteoporosis Pseudoglioma. On interventions, the most commonly used approaches for handling childhood blindness include gene therapy vectors like AAV RPE65, antisense oligonucleotides like QR-110, and repurposed pharmacological agents such as lithium and dantrolene sodium. All studies included children within their target populations, and most were early-phase (Phase 1/2) trials with small sample sizes (11-26 participants). Primary outcomes focused on safety, while secondary outcomes assessed visual function and biochemical changes.
Conclusion:
Although limited in number, current clinical trials represent a promising shift toward targeted therapies for childhood blindness. The dominance of early-phase studies highlights the need for expanded, multicenter, and later-phase trials. Future research should aim to improve trial accessibility, standardize outcome measures, and ensure ethical conduct in pediatric populations.
More Related Videos
07:43Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Tissue in a Feline Large Animal Model
Published on: August 5, 2021
08:38Electroretinogram Recording for Infants and Children under Anesthesia to Achieve Optimal Dark Adaptation and International Standards
Published on: September 3, 2020
